Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement

Christine E. Ryan, Rebecca L. Zon, Robert Redd, David C. Fisher, Roni Shouval, Anita Kumar, Jennifer L. Crombie, Hossein Sadrzadeh, Austin I. Kim, Lakshmi Nayak, Ugonma N. Chukwueke, Caron A. Jacobson, Matthew J. Frigault, M. Lia Palomba, Philippe Armand, Zachary Epstein-Peterson, Reid W. Merryman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited. We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3). Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.

Original languageEnglish
Pages (from-to)774-780
Number of pages7
JournalBritish Journal of Haematology
Volume203
Issue number5
Early online date16 Aug 2023
DOIs
StatePublished - Dec 2023
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2023 British Society for Haematology and John Wiley & Sons Ltd.

Keywords

  • CNS
  • cellular therapies
  • non-Hodgkin lymphoma

Fingerprint

Dive into the research topics of 'Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement'. Together they form a unique fingerprint.

Cite this